Drug intelligence / Profile preview

IMM2501

Development stage: Preclinical
Lead developer: ImmuneOnco
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IMM2501 is a preclinical-stage bispecific monoclonal antibody developed by ImmuneOnco. It is designed to simultaneously target and block two key immune checkpoints: Programmed cell death 1 ligand 1 (PD-L1) and Lymphocyte activation gene 3 protein (LAG-3). By inhibiting these pathways, IMM2501 aims to restore the anti-tumor activity of T cells and overcome resistance mechanisms often associated with single-checkpoint inhibition. The drug is currently being investigated for the treatment of various solid tumors.

Targets

LAG3 (Lymphocyte activation Gene-3 protein)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on IMM2501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMM2501.

Explore the full profile